<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Dynavax Technologies Corporation

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Dynavax Technologies Corporation

    Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. We develop immunotherapies based on cutting-edge Toll-Like Receptor (TLR) biology and its ability to modulate the immune system. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Robert L. Coffman, PhD
    • FOUNDED
      1996
    • EMPLOYEES
      101-250
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Galapagos NV

    Galapagos NV

    Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...

    Galapagos develops therapies with proprietary, ...

    Filing Type:    PU
    PatientDirected Inc.

    PatientDirected Inc.

    Unique and disruptive, PatientDirected.io benefits the patient first. It intends t...

    Unique and disruptive, PatientDirected.io benef...

    Fundraising Status:    EC
    Filing Type:    CF
    Dare Bioscience, Inc.

    Dare Bioscience, Inc.

    DarĂŠ Bioscience is a clinical-stage biopharmaceutical company committed to the ad...

    DarĂŠ Bioscience is a clinical-stage biopharmac...

    Filing Type:    PU
    Neurocarrus Inc

    Neurocarrus Inc

    Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...

    Neurocarrus is developing a breakthrough therap...

    Amount Raised:    $344,168.00
    Fundraising Status:    EC
    Filing Type:    CF
    Sienna Biopharmaceuticals, Inc.

    Sienna Biopharmaceuticals, Inc.

    Sienna Biopharmaceuticals, Inc. is a clinical–stage biopharmaceutical company fo...

    Sienna Biopharmaceuticals, Inc. is a clinicalâ€...

    Filing Type:    PU
    TG Therapeutics, Inc.

    TG Therapeutics, Inc.

    TG Therapeutics is a biopharmaceutical company focused on the acquisition, develop...

    TG Therapeutics is a biopharmaceutical company ...

    Filing Type:    PU
    Idera Pharmaceuticals, Inc.

    Idera Pharmaceuticals, Inc.

    Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing nov...

    Idera Pharmaceuticals is a clinical-stage bioph...

    Filing Type:    PU
    Takeda Pharmaceutical Co., Ltd.

    Takeda Pharmaceutical Co., Ltd.

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-base...

    Takeda Pharmaceutical Company Limited (TSE:4502...

    Filing Type:    PU
    Genocea Biosciences, Inc.

    Genocea Biosciences, Inc.

    Genocea is a biopharmaceutical company developing personalized cancer immunotherap...

    Genocea is a biopharmaceutical company developi...

    Filing Type:    PU
    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    Kiniksa Pharmaceuticals, Ltd.

    Kiniksa Pharmaceuticals, Ltd.

    We are a biopharmaceutical company focused on discovering, acquiring, developing a...

    We are a biopharmaceutical company focused on d...

    Filing Type:    PU
    Equillium, Inc.

    Equillium, Inc.

    Equillium is a biotechnology company leveraging deep understanding of immunobiolog...

    Equillium is a biotechnology company leveraging...

    Filing Type:    PU
    Galapagos NV

    Galapagos NV

    Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...

    Galapagos develops therapies with proprietary, ...

    Filing Type:    PU
    ChemoCentryx, Inc.

    ChemoCentryx, Inc.

    ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...

    ChemoCentryx is a biopharmaceutical company foc...

    Filing Type:    PU
    Gossamer Bio, Inc.

    Gossamer Bio, Inc.

    Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering,...

    Gossamer Bio is a clinical-stage biopharmaceuti...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.